Pipeline
EVOQ Programs
Celiac Disease (CeD)
Type 1 Diabetes (T1D)
Primary Biliary Cholangitis (PBC)
Pemphigus Vulgaris (PV)
Multiple Sclerosis (MS)
Partnered Programs
PARTNER: GILEAD
Rheumatoid Arthritis (RA)
Systemic lupus erythematosus (SLE)
Celiac Disease (CeD)
EVOQ PROGRAM
Celiac disease is a serious, chronic autoimmune disease that affects approximately 1% of the world's population. For individuals suffering from CeD, ingestion of gluten leads to damage of the villi in the small intestine causing chronic diarrhea, abdominal distention, and poor absorption of nutrients. This can lead to additional serious conditions. Celiac disease patients are 4 times more likely to develop small bowel and GI cancer, 2 times more likely to develop coronary artery disease, and are at significant risk of developing early onset osteoporosis. Currently, there are no cures for CeD, and management of the disease requires lifelong adherence to a strict gluten-free diet.
Type 1 Diabetes (T1D)
EVOQ PROGRAM
Type 1 diabetes is an autoimmune disease driven by immune autoreactivity to insulin-producing islet cells in the pancreas. The destruction of pancreatic islet cells results in the loss of insulin production and hyperglycemia, which damages tissue and affects the normal functioning of multiple organs in the body. Close to 10 million people around the world live with Type 1 diabetes and diagnosis is increasing at four times the rate of global population growth. It is a progressive disease and there are no cures. Management of the disease requires patients to adhere to a strict diet, monitor blood glucose levels throughout the day, and administer daily insulin injections to maintain normal glycemic control.
Primary Biliary Cholangitis (PBC)
EVOQ PROGRAM
Primary biliary cholangitis is a chronic, progressive autoimmune disease caused by the negative immune response towards proteins in liver bile duct cells. This leads to immune-mediated destruction of bile ducts and irreversible damage to the liver tissue. The disease usually progresses to terminal stages over 15 to 20 years, ultimately requiring liver transplant. There are no cures and patients with PBC are at a significant increased risk of early death with highest risk occurring within first year after diagnosis.
Pemphigus Vulgaris (PV)
EVOQ PROGRAM
Pemphigus is an autoimmune disease defined as a group of life-threatening blistering disorders in the mucous membranes and skin The intraepidermal blistering observed in pemphigus occurs due to a negative immune response that results in the deposition of autoantibodies against epidermal cell surface antigens within the epithelium of mucous membranes or skin. Complications include malnutrition due to painful sores in the mouth making it difficult to eat; scarring and changes to skin color, and risk of sepsis if skin infections spread to the bloodstream. There is no cure.
Multiple Sclerosis (MS)
EVOQ PROGRAM
Multiple sclerosis is a progressive demyelinating disease of the CNS in which the immune system attacks the myelin sheath in the brain and spinal cord. Scar tissue forms interfering with the brain’s ability to function and properly operate the body. Complications from the disease include vision problems, tiredness, trouble walking and keeping balance, and numbness or weakness in the arms and legs. Close to 3 million people worldwide suffer from MS and there are no curs. Current therapies focus on reducing the frequency and severity of relapses, slowing disease progression, and managing symptoms, to improve quality of life.
Contact Us
Have questions or want to learn more about our work? We’d love to hear from you! Whether you're a potential partner, researcher, or someone interested in our therapies, we're here to connect. Reach out to us and let’s start the conversation.